A hand holding a plain white oval tablet between finger and thumb, with a second hand holding a glass of water beside it, against a pale wall and a striped shirt.

The Wegovy Pill Is on Private Prescription in Australia From 20 November: What the TGA Approved and What It Costs

The Wegovy tablet, made by Novo Nordisk, could be prescribed privately in Australia from Friday 20 November, RACGP newsGP reported […]

The Wegovy tablet, made by Novo Nordisk, could be prescribed privately in Australia from Friday 20 November, RACGP newsGP reported on Thursday 19 November. It is the first oral GLP-1 medicine approved for weight management to make it to Australian shelves, according to the same report.

The Therapeutic Goods Administration (TGA) approved the tablet for registration in the Australian Register of Therapeutic Goods (ARTG) in a decision dated 2 November 2026, with the registration dated 3 November 2026, according to its decision summary, which was published on 11 November 2026.

Would you choose a daily tablet over a weekly injection, if either suited you?

Choose an answer, then select Vote.

What the TGA Approved

The decision summary for Wegovy (semaglutide) describes the tablet as a new dosage form. It is approved for adults in four strengths, 1.5 mg, 4 mg, 9 mg and 25 mg, for chronic weight management, in combination with a reduced energy diet and increased physical activity, and for lowering the risk of serious cardiovascular events in people who already have cardiovascular disease, the TGA says.

The approved indication for weight management covers patients diagnosed as obese with a Body Mass Index (BMI) of 30 or more, or overweight with a BMI of 27 or more and one weight-related health issue, the TGA says.

The tablet contains semaglutide, which is already registered in Australia as an injection. The TGA says the tablets “offer an alternative treatment option, instead of the injection”. It also says that using Wegovy tablets or injections at the same time as other semaglutide or GLP-1 receptor agonist medicines is not recommended.

Trial Results and Side Effects

The TGA cites one main study, OASIS-4, in which 76.3 per cent of participants on the 25 mg tablet achieved weight loss of 5 per cent or more, against 30.5 per cent on placebo. 7NEWS adds that, in separate clinical trials, adults on the highest tablet dose lost about 14 per cent of body weight on average over one year, and those on the 2.4 mg weekly injection about 15 per cent over 68 weeks.

Most reported side effects were non-serious and mild or moderate, the TGA says. The most commonly reported were nausea and vomiting, constipation, indigestion, diarrhoea, belching, abdominal pain, headache, dizziness and fatigue. 7NEWS names pancreatitis as a more serious risk. The TGA points to the Consumer Medicine Information leaflet and the Product Information for comprehensive side-effect information.

Where It Is Available

RACGP newsGP reported that half a million Australians used GLP-1 injections in 2025. Dr Terri-Lynne South of the RACGP told newsGP: “Until now, GLP-1 medicines for weight management have only been available as injections. Now, for the first time, there’s an oral option.”

7NEWS watched the first boxes unpacked at a pharmacy in Wetherill Park, in western Sydney, on Thursday 19 November. Pharmacist Catherine Bronger told 7NEWS she expected community pharmacies to have the tablet by Friday 20 November or over the weekend of 21 and 22 November, and that stock may take several days to reach some pharmacies. She said on Thursday 19 November: “There will be varying prices depending on what pharmacy you go to and varying availability over the next week.”

Dr Ana Svensson, Novo Oceania’s senior director of medical and regulatory, said availability in Australia “opens a door” for eligible patients, RACGP newsGP reported.

RACGP newsGP also reported on Thursday 19 November that rival manufacturer Lilly’s weight-loss pill orforglipron, sold as Foundayo, has been approved on the ARTG and “will be ready for prescriptions ‘in the coming days'”.

Cost and Subsidy

RACGP newsGP reported prices by dose: $260 for 1.5 mg, $270 for 4 mg, $280 for 9 mg and $395 for 25 mg. 7NEWS describes the same figures as Novo Nordisk’s recommended price for a month’s supply. RACGP newsGP says the final price may vary with the pharmacy and services provided.

The tablet launched without a Pharmaceutical Benefits Scheme (PBS) subsidy, so patients pay the full pharmacy price, 7NEWS reported. As at Thursday 19 November, the injectable Wegovy was yet to be listed on the PBS despite a recommendation from the Pharmaceutical Benefits Advisory Committee made almost a year earlier, RACGP newsGP reported.

Dr South, the immediate past chair of RACGP Specific Interests Obesity Management, and its chair, Dr Mark Mellor, say the tablet widens choice, and newsGP reports that Dr South agrees cost remains the biggest barrier. “Like the injectable, it’s only available on private prescription. Until obesity medicines are subsidised, access will be determined by what people can afford rather than by clinical need,” Dr South told newsGP. Dr Mellor told newsGP that “we still don’t have PBS funding for these treatments, so we’re calling on the Government to look at how these treatments can be funded.”

The TGA also featured in wrp’s report of 1 November on a coroner’s findings on unapproved peptides and call for a TGA review. More health coverage is in our Health archive.

RACGP newsGP reported on Thursday 19 November that GPs would be able to write a private prescription for the tablet from Friday 20 November. The prices above are Novo Nordisk’s recommended prices as reported on 19 November, and 7NEWS reported that the tablet launched without a PBS subsidy.

Sources: Therapeutic Goods Administration, “Wegovy (semaglutide)” Australian Prescription Medicine Decision Summary, published 11 November 2026 (https://www.tga.gov.au/resources/auspmd/wegovy-semaglutide); RACGP newsGP, “First weight-loss pill now available to prescribe”, 19 November 2026 (https://www1.racgp.org.au/newsgp/clinical/wegovy-pill-now-available-to-prescribe); 7NEWS, “Wonder semaglutide pill Wegovy arrives in Australia offering patients a needle-free alternative to a weight-loss jab”, 19 November 2026 (https://7news.com.au/lifestyle/weight-loss/wonder-semaglutide-pill-wegovy-arrives-in-australia-offering-patients-a-needle-free-alternative-to-a-weight-loss-jab-c-23185864)

Photo: JESHOOTS.com, CC0, via Wikimedia Commons.

Stock photograph of a plain white tablet and a glass of water, used here for illustration only. It does not show the Wegovy tablet or its packaging.

Scroll to Top